Morgan Stanley lowered the firm’s price target on Bath & Body Works to $51 from $56 but keeps an Overweight rating on the shares. The firm is updating its discount cash flow valuation model on the stock, though it also remains confident in the company’s ability to deliver mid-to-high single digit topline growth and 20% or higher EBIT margin over the long term, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBWI:
- Bath & Body Works to Present at the Goldman Sachs 31st Annual Global Retailing Conference
- Bath & Body Works price target lowered to $50 from $52 at BMO Capital
- Bath & Body Works price target lowered to $42 from $51 at Raymond James
- Bath & Body Works price target lowered to $45 from $54 at BofA
- Bath & Body Works price target lowered to $45 from $54 at Baird
Questions or Comments about the article? Write to editor@tipranks.com